Roy Bicknell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2846000/publications.pdf Version: 2024-02-01



POV RICKNELL

#	Article	IF	CITATIONS
1	Tumour vascular targeting. Nature Reviews Cancer, 2005, 5, 436-446.	28.4	545
2	Magic Roundabout Is a New Member of the Roundabout Receptor Family That Is Endothelial Specific and Expressed at Sites of Active Angiogenesis. Genomics, 2002, 79, 547-552.	2.9	299
3	Delta4, an endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation, 2001, 69, 135-144.	1.9	262
4	Enhancement of Tumor Growth and Vascular Density by Transfection of Vascular Endothelial Cell Growth Factor Into MCF-7 Human Breast Carcinoma Cells. Journal of the National Cancer Institute, 1995, 87, 213-219.	6.3	250
5	Anticancer strategies involving the vasculature. Nature Reviews Clinical Oncology, 2009, 6, 395-404.	27.6	234
6	Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry, 1992, 31, 12141-12146.	2.5	191
7	Suppression of Luteal Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor ¹ . Endocrinology, 2000, 141, 995-1000.	2.8	189
8	Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochemical Journal, 1998, 334, 1-8.	3.7	187
9	Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends in Pharmacological Sciences, 1995, 16, 57-66.	8.7	185
10	Plateletâ€derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study. Journal of Pathology, 1995, 176, 183-190.	4.5	175
11	Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB Journal, 2005, 19, 121-123.	0.5	162
12	Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis, 2008, 11, 13-21.	7.2	155
13	EndoPDI, a Novel Protein-disulfide Isomerase-like Protein That Is Preferentially Expressed in Endothelial Cells Acts as a Stress Survival Factor. Journal of Biological Chemistry, 2003, 278, 47079-47088.	3.4	149
14	Novel growth regulatory factors and tumour angiogenesis. European Journal of Cancer & Clinical Oncology, 1991, 27, 781-785.	0.7	141
15	Repulsive axon guidance molecule Slit3 is a novel angiogenic factor. Blood, 2009, 114, 4300-4309.	1.4	132
16	Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends in Pharmacological Sciences, 2002, 23, 576-582.	8.7	130
17	PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. Oncogene, 1998, 16, 409-415.	5.9	125
18	URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES. Journal of Urology, 1999, 161, 799-804.	0.4	118

#	Article	IF	CITATIONS
19	Heterogeneity of the endothelial cell and its role in organ preference of tumour metastasis. Trends in Pharmacological Sciences, 1991, 12, 462-467.	8.7	117
20	Neuronal clues to vascular guidance. Experimental Cell Research, 2006, 312, 668-675.	2.6	111
21	Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated <i>via</i> WASP and other actin nucleationâ€promoting factors. FASEB Journal, 2009, 23, 513-522.	0.5	106
22	Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene, 2002, 21, 2815-2821.	5.9	102
23	Peptide blockade of HIFÂ degradation modulates cellular metabolism and angiogenesis. Proceedings of the United States of America, 2002, 99, 10423-10428.	7.1	101
24	Interleukin-4 is a potent mitogen for capillary endothelium. Biochemical and Biophysical Research Communications, 1991, 174, 1287-1293.	2.1	95
25	NOVELANGIOGENICSIGNALINGPATHWAYS ANDVASCULARTARGETS. Annual Review of Pharmacology and Toxicology, 2004, 44, 219-238.	9.4	95
26	Changes in the coordination geometry of the active-site metal during catalysis of benzylpenicillin hydrolysis by Bacillus cereus .betalactamase II. Biochemistry, 1986, 25, 7208-7215.	2.5	82
27	Hepatitis C Virus Infection Reduces Hepatocellular Polarity in a Vascular Endothelial Growth Factor–Dependent Manner. Gastroenterology, 2010, 138, 1134-1142.	1.3	73
28	Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB Journal, 2003, 17, 1-25.	0.5	72
29	Vascular Endothelial Growth Factor (VEGF)-D and VEGF-A Differentially Regulate KDR-mediated Signaling and Biological Function in Vascular Endothelial Cells. Journal of Biological Chemistry, 2004, 279, 36148-36157.	3.4	70
30	The isolation and culture of microvascular endothelium. Journal of Cell Science, 1993, 105, 269-273.	2.0	68
31	Angiogenic Signalling Pathways. Methods in Molecular Biology, 2009, 467, 3-24.	0.9	67
32	Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium. , 1998, 185, 402-408.		66
33	Expression of VEGF in routinely fixed material using a new monoclonal. , 1998, 186, 313-318.		65
34	Suppression of Luteal Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor. Endocrinology, 2000, 141, 995-1000.	2.8	62
35	Heparin Octasaccharides Inhibit Angiogenesis In vivo. Clinical Cancer Research, 2005, 11, 8172-8179.	7.0	61
36	Endothelial Cell-Specific Expression of Tumor Necrosis Factor- <i>α</i> from the KDR or E-Selectin Promoters Following Retroviral Delivery. Human Gene Therapy, 1997, 8, 2239-2247.	2.7	58

#	Article	IF	CITATIONS
37	MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome. Cancer Research, 2016, 76, 2314-2326.	0.9	58
38	Regulation of Wnt5a mRNA Expression in Human Mammary Epithelial Cells by Cell Shape, Confluence, and Hepatocyte Growth Factor. Journal of Biological Chemistry, 1995, 270, 12851-12856.	3.4	55
39	Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. , 1998, 75, 706-712.		54
40	Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. Journal of Pathology, 2000, 192, 234-242.	4.5	52
41	RhoJ interacts with the GIT-PIX complex and regulates focal adhesion disassembly. Journal of Cell Science, 2014, 127, 3039-51.	2.0	51
42	Câ€ŧype lectin domain group 14 proteins in vascular biology, cancer and inflammation. FEBS Journal, 2019, 286, 3299-3332.	4.7	51
43	Breast cancer angiogenesis — new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Research and Treatment, 1996, 38, 97-108.	2.5	50
44	Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. Journal of Pathology, 2002, 196, 416-422.	4.5	50
45	Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. Journal of Cell Science, 2006, 119, 910-922.	2.0	48
46	A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics, 2008, 9, 153.	2.8	47
47	Angiogenesis in the Corpus Luteum of Early Pregnancy in the Marmoset and the Effects of Vascular Endothelial Growth Factor Immunoneutralization on Establishment of Pregnancy. Biology of Reproduction, 2002, 67, 1180-1188.	2.7	45
48	Interaction of anions with the active site of carboxypeptidase A. Biochemistry, 1988, 27, 1050-1057.	2.5	40
49	Adrenomedullin and the microvasculature. Trends in Pharmacological Sciences, 2002, 23, 101-103.	8.7	39
50	The thioredoxin-like fold: Hidden domains in protein disulfide isomerases and other chaperone proteins. BioEssays, 2003, 25, 603-611.	2.5	38
51	Electronic spectroscopy of cobalt angiotensin converting enzyme and its inhibitor complexes. Biochemistry, 1987, 26, 7291-7297.	2.5	35
52	Steroids and the Endometrium. Current Medicinal Chemistry, 2000, 7, 543-560.	2.4	35
53	Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer, 1994, 74, 1021-1025.	4.1	34
54	Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. International Journal of Oncology, 2005, 27, 401.	3.3	33

#	Article	IF	CITATIONS
55	ECSM2, An Endothelial Specific Filamin A Binding Protein That Mediates Chemotaxis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1640-1646.	2.4	32
56	Sprouting angiogenesis is regulated by shedding of the Câ€ŧype lectin family 14, member A (CLEC14A) ectodomain, catalyzed by rhomboidâ€ŀike 2 protein (RHBDL2). FASEB Journal, 2016, 30, 2311-2323.	0.5	30
57	Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays. Angiogenesis, 1999, 3, 211-219.	7.2	29
58	Regulation of the Expression of the Angiogenic Enzyme Platelet-Derived Endothelial Cell Growth Factor/ Thymidine Phosphorylase in Endometrial Isolates by Ovarian Steroids and Cytokines*. Endocrinology, 1997, 138, 4921-4930.	2.8	28
59	The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. Angiogenesis, 1998, 2, 203-217.	7.2	26
60	Anti-angiogenic alternatives to VEGF blockade. Clinical and Experimental Metastasis, 2016, 33, 197-210.	3.3	26
61	Isolation and properties in culture of human adrenal capillary endothelial cells. Biochemical and Biophysical Research Communications, 1991, 174, 903-908.	2.1	25
62	Protease susceptibility of zinc - and APO-carboxypeptidase A. Biochemical and Biophysical Research Communications, 1985, 133, 787-793.	2.1	24
63	Shear stress, tip cells and regulators of endothelial migration. Biochemical Society Transactions, 2011, 39, 1571-1575.	3.4	24
64	Thymidine phosphorylase expression in endometrial carcinomas. Clinical and Experimental Metastasis, 1999, 17, 445-450.	3.3	23
65	Therapeutic targeting of the tumor vasculature. Seminars in Radiation Oncology, 2004, 14, 222-232.	2.2	23
66	Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer, 1994, 74, 1021-1025.	4.1	23
67	CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth. JCI Insight, 2020, 5, .	5.0	23
68	Glutamate dependent NMDA receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer. Oncotarget, 2016, 7, 20440-20454.	1.8	23
69	A spectral study of cobalt(II)-substituted Bacillus cereus phospholipase C. Biochemistry, 1986, 25, 4219-4223.	2.5	20
70	Expression and mutagenesis of recombinant human and murine erythropoietins in Escherichia coli. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1995, 1261, 35-43.	2.4	20
71	ROLE OF THYMIDINE PHOSPHORYLASE IN AN IN VITRO MODEL OF HUMAN BLADDER CANCER INVASION. Journal of Urology, 2002, 167, 1482-1486.	0.4	20
72	Angiogenesis in Breast Cancer Annals of the New York Academy of Sciences, 1993, 698, 71-84.	3.8	19

#	Article	IF	CITATIONS
73	Angiogenesis in the endometrium. , 1998, 2, 29-35.		17
74	Robo4 vaccines induce antibodies that retard tumor growth. Angiogenesis, 2015, 18, 83-95.	7.2	15
75	Inference of Low and High-Grade Glioma Gene Regulatory Networks Delineates the Role of Rnd3 in Establishing Multiple Hallmarks of Cancer. PLoS Genetics, 2015, 11, e1005325.	3.5	14
76	In Vivo Evidence for Platelet-Induced Physiological Angiogenesis by a COX Driven Mechanism. PLoS ONE, 2014, 9, e107503.	2.5	13
77	Preparation of the iodine-124 derivative of the Bolton-Hunter reagent ([1241]I-SHPP) and its use for labelling a VEGF antibody as a PET tracer. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 1077-1090.	1.0	12
78	Functionally defining the endothelial transcriptome, from Robo4 to ECSCR. Biochemical Society Transactions, 2009, 37, 1214-1217.	3.4	12
79	Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors. Cancer Research, 2017, 77, 1008-1020.	0.9	12
80	Tube-Forming Assays. Methods in Molecular Biology, 2016, 1430, 149-157.	0.9	11
81	Antiangiogenic Activity of a Domain Deletion Mutant of Tissue Plasminogen Activator Containing Kringle 2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 736-741.	2.4	10
82	An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours. Journal of Pathology: Clinical Research, 2020, 6, 308-319.	3.0	10
83	Expression of Terminally Glycosylated Calcitonin Receptor–Like Receptor in Uterine Leiomyoma: Endothelial Phenotype and Association with Microvascular Density. Clinical Cancer Research, 2006, 12, 5648-5658.	7.0	9
84	Pulmonary MicroRNA Changes Alter Angiogenesis in Chronic Obstructive Pulmonary Disease and Lung Cancer. Biomedicines, 2021, 9, 830.	3.2	9
85	Expression of VEGF in routinely fixed material using a new monoclonal. Journal of Pathology, 1998, 186, 313-318.	4.5	6
86	Cell Migration and the Boyden Chamber. , 2001, 58, 047-054.		4
87	Bioinformatic Methods for Finding Differentially Expressed Genes in cDNA Libraries, Applied to the Identification of Tumour Vascular Targets. Methods in Molecular Biology, 2011, 729, 99-119.	0.9	4
88	Therapeutic Inhibition of Angiogenesis. Molecular Biotechnology, 2003, 25, 185-200.	2.4	3
89	URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES. Journal of Urology, 1999, , 799-804.	0.4	3
90	COS-1 cell expression and one-step affinity protein purification and activity of epitope-tagged human erythropoietin and of site-directed mutants. BBA - Proteins and Proteomics, 1997, 1340, 13-20.	2.1	2

#	Article	IF	CITATIONS
91	Vascular Targeting Approaches to Treat Cancer. , 2013, , 59-95.		2
92	Therapeutic Inhibition of Angiogenesis. , 2001, 46, 003-026.		1
93	Retinal anti-angiogenesis by a new route. Nature Biotechnology, 2008, 26, 528-529.	17.5	1
94	AVEXIS technology identifies novel platelet-leukocyte binding partners including CD148-CD300a. Blood Advances, 2021, 5, 5016-5019.	5.2	1
95	ROLE OF THYMIDINE PHOSPHORYLASE IN AN IN VITRO MODEL OF HUMAN BLADDER CANCER INVASION. Journal of Urology, 2002, , 1482-1486.	0.4	1
96	Monoclonal Antibodies That Recognize the Type-2 Activin Receptor, ACTR2. Hybridoma, 1994, 13, 199-203.	0.6	0
97	Angiopoietins. Angiogenesis, 1997, 1, 15-15.	7.2	0
98	Assessment of Angiogenic Factors: The Chick Chorioallantoic Membrane Assay. , 2001, 58, 119-124.		0
99	Development of Antibody-Based Vaccines Targeting the Tumor Vasculature. Methods in Molecular Biology, 2016, 1403, 839-849.	0.9	0
100	04.08â€Members of the type 14 c-type lectin family protect from inflammatory arthritis but differentially regulate bone erosions. , 2017, , .		0
101	Targeting Gene Therapy to the Tumor Vasculature. , 2002, , 453-473.		0
102	The Discovery and Characterisation of Tumour Endothelial Markers. , 2010, , 31-48.		0
103	Angiogenic Polypeptides in Breast Cancer: Expression of Mrna's in Primary Human Tumours, MCF-7 Cell Transfection and Xenograft Models. , 1998, , 213-221.		0